Skip to main content
Immunology Laboratory

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Please see our latest guidance on face masks.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Beta Interferon Neutralising antibodies

Please note: Beta Interferon Neutralising Antibody testing is performed by a referral laboratory. This assay is only available to members of Oxford University Hospitals NHS Foundation Trust.

Multiple sclerosis patients receiving treatment with recombinant interferon-beta (IFN-β) products often develop IFN-β binding antibodies (BAbs) and neutralising antibodies (NAbs). Quantification of the BAbs and NAbs is important as they may reduce the clinical efficacy of the treatment. The current method used is a cell based luciferase reporter gene assay for the measurement of NAbs to IFN-β in serum patients with multiple sclerosis. The results of the assay are aimed to inform the clinician as to the likely efficacy of the current therapy.

This assay is performed at a referral laboratory (external users requiring serum Beta Interferon Neutralising antibody levels are advised to contact the referral laboratory directly):

Neuroimmunology & CSF Laboratory (NICL)
The National Hospital for Neurology & Neurosurgery
9th Floor
Queens Square

Specimen requirements

Serum 1ml; plasma is NOT acceptable



Laboratory turnaround time

35 days

Laboratory method


Reference range/units

Units = NU

Negative <20 NU

Low Positive = 20 – 100 NU

Positive = 100 – 600 NU

High Positive >600 NU

Associated tests


Shipping and storage

Internal hospital transport/courier.

Ensure delivery Monday to Friday 07:00 - 17:30.

Further information and contact details

For further information, email